OBJECTIVE: To determine whether serum trace metals and oxidative species are related to abnormal cognition in AD. METHODS: The authors studied serum peroxides, copper, iron, transferrin, and antioxidant capacity in 79 patients with AD (mean age 74.3 years; 25 men, 54 women) and in 76 cognitively normal individuals (mean age 70.1 years; 33 men, 43 women). The relation of these oxidative and trace metals to APOE epsilon4 allele frequency, neuropsychological performance, and cerebrovascular or atrophic burden, as estimated by brain MRI and ultrasonography of cerebral vessels, was evaluated. RESULTS: Copper level was higher (p < 0.001) in subjects with AD than control subjects (specificity = 95%, sensitivity = 60%) with a cutoff serum level of 16 micro mol/L (1.02 mg/L). An increase of 1 micro mol/L in serum copper accounted for 80% of the risk of having AD and correlated with poor neuropsychological performance and medial temporal lobe atrophy (p < 0.03). Antioxidant capacity decreased and correlated with medial temporal lobe atrophy (p < 0.009) and with APOE epsilon4 allele (p = 0.004). CONCLUSIONS: Copper may play a role in neurodegenerative processes in AD, and serum copper measurement may prove to be a peripheral diagnostic marker for AD.
OBJECTIVE: To determine whether serum trace metals and oxidative species are related to abnormal cognition in AD. METHODS: The authors studied serum peroxides, copper, iron, transferrin, and antioxidant capacity in 79 patients with AD (mean age 74.3 years; 25 men, 54 women) and in 76 cognitively normal individuals (mean age 70.1 years; 33 men, 43 women). The relation of these oxidative and trace metals to APOE epsilon4 allele frequency, neuropsychological performance, and cerebrovascular or atrophic burden, as estimated by brain MRI and ultrasonography of cerebral vessels, was evaluated. RESULTS:Copper level was higher (p < 0.001) in subjects with AD than control subjects (specificity = 95%, sensitivity = 60%) with a cutoff serum level of 16 micro mol/L (1.02 mg/L). An increase of 1 micro mol/L in serum copper accounted for 80% of the risk of having AD and correlated with poor neuropsychological performance and medial temporal lobe atrophy (p < 0.03). Antioxidant capacity decreased and correlated with medial temporal lobe atrophy (p < 0.009) and with APOE epsilon4 allele (p = 0.004). CONCLUSIONS:Copper may play a role in neurodegenerative processes in AD, and serum copper measurement may prove to be a peripheral diagnostic marker for AD.
Authors: Shino Magaki; Ravi Raghavan; Claudius Mueller; Kerby C Oberg; Harry V Vinters; Wolff M Kirsch Journal: Neurosci Lett Date: 2007-03-03 Impact factor: 3.046
Authors: H Kessler; F-G Pajonk; P Meisser; T Schneider-Axmann; K-H Hoffmann; T Supprian; W Herrmann; R Obeid; G Multhaup; P Falkai; T A Bayer Journal: J Neural Transm (Vienna) Date: 2006-06-01 Impact factor: 3.575
Authors: Pu Chun Ke; Marc-Antonie Sani; Feng Ding; Aleksandr Kakinen; Ibrahim Javed; Frances Separovic; Thomas P Davis; Raffaele Mezzenga Journal: Chem Soc Rev Date: 2017-10-30 Impact factor: 54.564
Authors: Itender Singh; Abhay P Sagare; Mireia Coma; David Perlmutter; Robert Gelein; Robert D Bell; Richard J Deane; Elaine Zhong; Margaret Parisi; Joseph Ciszewski; R Tristan Kasper; Rashid Deane Journal: Proc Natl Acad Sci U S A Date: 2013-08-19 Impact factor: 11.205
Authors: P K Lam; D Kritz-Silverstein; E Barrett Connor; D Milne; F Nielsen; A Gamst; D Morton; D Wingard Journal: J Nutr Health Aging Date: 2008-01 Impact factor: 4.075
Authors: Rosanna Squitti; Carlo C Quattrocchi; Gloria Dal Forno; Piero Antuono; David R Wekstein; Concetta R Capo; Carlo Salustri; Paolo M Rossini Journal: Biomark Insights Date: 2007-02-07